{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T14:52:57Z","timestamp":1781880777357,"version":"3.54.5"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1038\/s41401-025-01745-x","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T06:53:34Z","timestamp":1772175214000},"page":"1840-1855","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A potential therapeutic effect of 84-B10 in MASLD through promotion of FASN degradation"],"prefix":"10.1038","volume":"47","author":[{"given":"Yi-peng","family":"Bai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-man","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang-ming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze-hua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-qi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang-xin","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-yang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei-cheng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deng-qiu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"key":"1745_CR1","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","volume":"24","author":"SL Friedman","year":"2018","unstructured":"Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24:908\u201322.","journal-title":"Nat Med"},{"key":"1745_CR2","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1002\/hep.32045","volume":"74","author":"Y Hu","year":"2021","unstructured":"Hu Y, He W, Huang Y, Xiang H, Guo J, Che Y, et al. Fatty acid synthase-suppressor screening identifies sorting nexin 8 as a therapeutic target for NAFLD. Hepatology. 2021;74:2508\u201325.","journal-title":"Hepatology"},{"key":"1745_CR3","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jhep.2023.03.039","volume":"79","author":"K Jin","year":"2023","unstructured":"Jin K, Shi Y, Zhang H, Zhangyuan G, Wang F, Li S, et al. A TNFalpha\/Miz1-positive feedback loop inhibits mitophagy in hepatocytes and propagates non-alcoholic steatohepatitis. J Hepatol. 2023;79:403\u201316.","journal-title":"J Hepatol"},{"key":"1745_CR4","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1038\/s41401-024-01412-7","volume":"46","author":"YW Liu","year":"2025","unstructured":"Liu YW, Luo RY, Liu AQ, Wang JW, Hu NP, Li WT, et al. Identification of chikusetsusaponin IVa as a novel lysine-specific demethylase 1 inhibitor that ameliorates high fat diet-induced MASLD in mice. Acta Pharmacol Sin. 2025;46:632\u201352.","journal-title":"Acta Pharmacol Sin"},{"key":"1745_CR5","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.jhep.2019.12.004","volume":"72","author":"Z Zhang","year":"2020","unstructured":"Zhang Z, Xu X, Tian W, Jiang R, Lu Y, Sun Q, et al. ARRB1 inhibits non-alcoholic steatohepatitis progression by promoting GDF15 maturation. J Hepatol. 2020;72:976\u201389.","journal-title":"J Hepatol"},{"key":"1745_CR6","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jhep.2023.03.039","volume":"79","author":"K Jin","year":"2023","unstructured":"Jin K, Shi Y, Zhang H, Zhangyuan G, Wang F, Li S, et al. A TNF\u03b1\/Miz1-positive feedback loop inhibits mitophagy in hepatocytes and propagates non-alcoholic steatohepatitis. J Hepatol. 2023;79:403\u201316.","journal-title":"J Hepatol"},{"key":"1745_CR7","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1038\/s41401-021-00836-9","volume":"43","author":"Y Chen","year":"2022","unstructured":"Chen Y, Xu YN, Ye CY, Feng WB, Zhou QT, Yang DH, et al. GLP-1 mimetics as a potential therapy for nonalcoholic steatohepatitis. Acta Pharmacol Sin. 2022;43:1156\u201366.","journal-title":"Acta Pharmacol Sin"},{"key":"1745_CR8","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41575-021-00523-4","volume":"19","author":"JV Lazarus","year":"2022","unstructured":"Lazarus JV, Mark HE, Anstee QM, Arab JP, Batterham RL, Castera L, et al. Advancing the global public health agenda for NAFLD: a consensus statement. Nat Rev Gastroenterol Hepatol. 2022;19:60\u201378.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1745_CR9","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1038\/s41401-024-01466-7","volume":"46","author":"SW Wong","year":"2025","unstructured":"Wong SW, Yang YY, Chen H, Xie L, Shen XZ, Zhang NP, et al. New advances in novel pharmacotherapeutic candidates for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) between 2022 and 2024. Acta Pharmacol Sin. 2025;46:1145\u201355.","journal-title":"Acta Pharmacol Sin"},{"key":"1745_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2015.80","volume":"1","author":"EM Brunt","year":"2015","unstructured":"Brunt EM, Wong VW, Nobili V, Day CP, Sookoian S, Maher JJ, et al. Nonalcoholic fatty liver disease. Nat Rev Dis Prim. 2015;1:15080.","journal-title":"Nat Rev Dis Prim"},{"key":"1745_CR11","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S2468-1253(24)00246-2","volume":"9","author":"R Loomba","year":"2024","unstructured":"Loomba R, Bedossa P, Grimmer K, Kemble G, Bruno Martins E, McCulloch W, et al. Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Gastroenterol Hepatol. 2024;9:1090\u2013100.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1745_CR12","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s40265-024-02045-0","volume":"84","author":"SJ Keam","year":"2024","unstructured":"Keam SJ. Resmetirom: first approval. Drugs. 2024;84:729\u201335.","journal-title":"Drugs"},{"key":"1745_CR13","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1172\/JCI23621","volume":"115","author":"KL Donnelly","year":"2005","unstructured":"Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest. 2005;115:1343\u201351.","journal-title":"J Clin Invest."},{"key":"1745_CR14","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.cmet.2005.04.002","volume":"1","author":"MV Chakravarthy","year":"2005","unstructured":"Chakravarthy MV, Pan Z, Zhu Y, Tordjman K, Schneider JG, Coleman T, et al. New\u201d hepatic fat activates PPARalpha to maintain glucose, lipid, and cholesterol homeostasis. Cell Metab. 2005;1:309\u201322.","journal-title":"Cell Metab"},{"key":"1745_CR15","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/hep.31000","volume":"72","author":"MM Syed-Abdul","year":"2020","unstructured":"Syed-Abdul MM, Parks EJ, Gaballah AH, Bingham K, Hammoud GM, Kemble G, et al. Fatty acid synthase inhibitor TVB-2640 reduces hepatic de novo lipogenesis in males with metabolic abnormalities. Hepatology. 2020;72:103\u201318.","journal-title":"Hepatology"},{"key":"1745_CR16","doi-asserted-by":"crossref","unstructured":"Xu S, Wu X, Wang S, Xu M, Fang T, Ma X, et al. TRIM56 protects against nonalcoholic fatty liver disease by promoting the degradation of fatty acid synthase. J Clin Invest. 2024;134:e166149.","DOI":"10.1172\/JCI166149"},{"key":"1745_CR17","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.cmet.2018.07.019","volume":"28","author":"U Bruning","year":"2018","unstructured":"Bruning U, Morales-Rodriguez F, Kalucka J, Goveia J, Taverna F, Queiroz KCS, et al. Impairment of angiogenesis by fatty acid synthase inhibition involves mTOR malonylation. Cell Metab. 2018;28:866\u201380.e15.","journal-title":"Cell Metab"},{"key":"1745_CR18","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.cmet.2013.05.017","volume":"18","author":"E Currie","year":"2013","unstructured":"Currie E, Schulze A, Zechner R, Walther TC, Farese RV Jr. Cellular fatty acid metabolism and cancer. Cell Metab. 2013;18:153\u201361.","journal-title":"Cell Metab"},{"key":"1745_CR19","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.cmet.2023.11.017","volume":"36","author":"RJ Wedan","year":"2024","unstructured":"Wedan RJ, Longenecker JZ, Nowinski SM. Mitochondrial fatty acid synthesis is an emergent central regulator of mammalian oxidative metabolism. Cell Metab. 2024;36:36\u201347.","journal-title":"Cell Metab"},{"key":"1745_CR20","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/s42255-023-00786-y","volume":"5","author":"YG Jeon","year":"2023","unstructured":"Jeon YG, Kim YY, Lee G, Kim JB. Physiological and pathological roles of lipogenesis. Nat Metab. 2023;5:735\u201359.","journal-title":"Nat Metab"},{"key":"1745_CR21","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1053\/j.gastro.2021.07.025","volume":"161","author":"R Loomba","year":"2021","unstructured":"Loomba R, Mohseni R, Lucas KJ, Gutierrez JA, Perry RG, Trotter JF, et al. TVB-2640 (FASN Inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled phase 2a trial. Gastroenterology. 2021;161:1475\u201386.","journal-title":"Gastroenterology"},{"key":"1745_CR22","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1111\/dom.14272","volume":"23","author":"C Beysen","year":"2021","unstructured":"Beysen C, Schroeder P, Wu E, Brevard J, Ribadeneira M, Lu W, et al. Inhibition of fatty acid synthase with FT-4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non-alcoholic fatty liver disease: Results from two early-phase randomized trials. Diab Obes Metab. 2021;23:700\u201310.","journal-title":"Diab Obes Metab"},{"key":"1745_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-19459-z","volume":"12","author":"M O\u2019Farrell","year":"2022","unstructured":"O\u2019Farrell M, Duke G, Crowley R, Buckley D, Martins EB, Bhattacharya D, et al. FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models. Sci Rep. 2022;12:15661.","journal-title":"Sci Rep"},{"key":"1745_CR24","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.freeradbiomed.2022.11.029","volume":"194","author":"J Fan","year":"2023","unstructured":"Fan J, Xu X, Li Y, Zhang L, Miao M, Niu Y, et al. A novel 3-phenylglutaric acid derivative (84-B10) alleviates cisplatin-induced acute kidney injury by inhibiting mitochondrial oxidative stress-mediated ferroptosis. Free Radic Biol Med. 2023;194:84\u201398.","journal-title":"Free Radic Biol Med"},{"key":"1745_CR25","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1002\/jcsm.12581","volume":"11","author":"D Xu","year":"2020","unstructured":"Xu D, Zhao L, Jiang J, Li S, Sun Z, Huang X, et al. A potential therapeutic effect of catalpol in Duchenne muscular dystrophy revealed by binding with TAK1. J Cachexia Sarcopenia Muscle. 2020;11:1306\u201320.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"1745_CR26","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1016\/j.cmet.2023.07.009","volume":"35","author":"T Chen","year":"2023","unstructured":"Chen T, Xu ZG, Luo J, Manne RK, Wang Z, Hsu CC, et al. NSUN2 is a glucose sensor suppressing cGAS\/STING to maintain tumorigenesis and immunotherapy resistance. Cell Metab. 2023;35:1782\u201398.e8.","journal-title":"Cell Metab"},{"key":"1745_CR27","doi-asserted-by":"publisher","first-page":"3110","DOI":"10.1002\/hep.32078","volume":"74","author":"Z Zhang","year":"2021","unstructured":"Zhang Z, Ji Z, He J, Lu Y, Tian W, Zheng C, et al. Guanine nucleotide-binding protein G(i) subunit alpha 2 exacerbates NASH progression by regulating peroxiredoxin 1-related inflammation and lipophagy. Hepatology. 2021;74:3110\u201326.","journal-title":"Hepatology"},{"key":"1745_CR28","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.addr.2020.06.027","volume":"159","author":"M Ten Hove","year":"2020","unstructured":"Ten Hove M, Pater L, Storm G, Weiskirchen S, Weiskirchen R, Lammers T, et al. The hepatic lipidome: from basic science to clinical translation. Adv Drug Deliv Rev. 2020;159:180\u201397.","journal-title":"Adv Drug Deliv Rev"},{"key":"1745_CR29","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1128\/MCB.01064-14","volume":"35","author":"SH Neo","year":"2015","unstructured":"Neo SH, Itahana Y, Alagu J, Kitagawa M, Guo AK, Lee SH, et al. TRIM28 is an E3 Ligase for ARF-mediated NPM1\/B23 SUMOylation that represses centrosome amplification. Mol Cell Biol. 2015;35:2851\u201363.","journal-title":"Mol Cell Biol"},{"key":"1745_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2022.102447","volume":"56","author":"Y Xie","year":"2022","unstructured":"Xie Y, Zhang Y, Sun A, Peng Y, Hou W, Xiang C, et al. The coupling of mitoproteolysis and oxidative phosphorylation enables tracking of an active mitochondrial state through MitoTimer fluorescence. Redox Biol. 2022;56:102447.","journal-title":"Redox Biol"},{"key":"1745_CR31","doi-asserted-by":"publisher","first-page":"e0135554","DOI":"10.1371\/journal.pone.0135554","volume":"10","author":"M Shiwa","year":"2015","unstructured":"Shiwa M, Yoneda M, Okubo H, Ohno H, Kobuke K, Monzen Y, et al. Distinct time course of the decrease in hepatic AMP-activated protein kinase and Akt phosphorylation in mice fed a high fat diet. PLoS One. 2015;10:e0135554.","journal-title":"PLoS One"},{"key":"1745_CR32","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","volume":"77","author":"ZM Younossi","year":"2023","unstructured":"Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77:1335\u201347.","journal-title":"Hepatology"},{"key":"1745_CR33","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1002\/hep.31150","volume":"71","author":"J Zhou","year":"2020","unstructured":"Zhou J, Zhou F, Wang W, Zhang XJ, Ji YX, Zhang P, et al. Epidemiological features of NAFLD from 1999 to 2018 in China. Hepatology. 2020;71:1851\u201364.","journal-title":"Hepatology"},{"key":"1745_CR34","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1158\/1078-0432.CCR-22-2807","volume":"29","author":"W Kelly","year":"2023","unstructured":"Kelly W, Diaz Duque AE, Michalek J, Konkel B, Caflisch L, Chen Y, et al. Phase II investigation of TVB-2640 (Denifanstat) with bevacizumab in patients with first relapse high-grade astrocytoma. Clin Cancer Res. 2023;29:2419\u201325.","journal-title":"Clin Cancer Res"},{"key":"1745_CR35","doi-asserted-by":"publisher","first-page":"60","DOI":"10.17925\/EE.2023.19.1.60","volume":"19","author":"G Karim","year":"2023","unstructured":"Karim G, Bansal MB. Resmetirom: an orally administered, smallmolecule, liver-directed, \u03b2-selective THR agonist for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. touchREV Endocrinol. 2023;19:60\u201370.","journal-title":"touchREV Endocrinol"},{"key":"1745_CR36","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.tem.2022.08.001","volume":"33","author":"E Hatziagelaki","year":"2022","unstructured":"Hatziagelaki E, Paschou SA, Schon M, Psaltopoulou T, Roden M. NAFLD and thyroid function: pathophysiological and therapeutic considerations. Trends Endocrinol Metab. 2022;33:755\u201368.","journal-title":"Trends Endocrinol Metab"},{"key":"1745_CR37","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/nrc2222","volume":"7","author":"JA Menendez","year":"2007","unstructured":"Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer. 2007;7:763\u201377.","journal-title":"Nat Rev Cancer"},{"key":"1745_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06463-6","volume":"15","author":"Y Xiao","year":"2024","unstructured":"Xiao Y, Yang Y, Xiong H, Dong G. The implications of FASN in immune cell biology and related diseases. Cell Death Dis. 2024;15:88.","journal-title":"Cell Death Dis"},{"key":"1745_CR39","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.tibs.2017.01.002","volume":"42","author":"S Hatakeyama","year":"2017","unstructured":"Hatakeyama S. TRIM family proteins: roles in autophagy, immunity, and carcinogenesis. Trends Biochem Sci. 2017;42:297\u2013311.","journal-title":"Trends Biochem Sci"},{"key":"1745_CR40","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1242\/jcs.068981","volume":"123","author":"F Okumura","year":"2010","unstructured":"Okumura F, Matsunaga Y, Katayama Y, Nakayama KI, Hatakeyama S. TRIM8 modulates STAT3 activity through negative regulation of PIAS3. J Cell Sci. 2010;123:2238\u201345.","journal-title":"J Cell Sci"},{"key":"1745_CR41","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1002\/hep.28971","volume":"65","author":"FJ Yan","year":"2017","unstructured":"Yan FJ, Zhang XJ, Wang WX, Ji YX, Wang PX, Yang Y, et al. The E3 ligase tripartite motif 8 targets TAK1 to promote insulin resistance and steatohepatitis. Hepatology. 2017;65:1492\u2013511.","journal-title":"Hepatology"},{"key":"1745_CR42","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s13577-022-00820-3","volume":"36","author":"J Zhang","year":"2023","unstructured":"Zhang J, Xie H, Yao J, Jin W, Pan H, Pan Z, et al. TRIM59 promotes steatosis and ferroptosis in non-alcoholic fatty liver disease via enhancing GPX4 ubiquitination. Hum Cell. 2023;36:209\u201322.","journal-title":"Hum Cell"},{"key":"1745_CR43","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.cell.2013.12.010","volume":"156","author":"WS Yang","year":"2014","unstructured":"Yang WS, SriRamaratnam R, Welsch ME, Shimada K, Skouta R, Viswanathan VS, et al. Regulation of ferroptotic cancer cell death by GPX4. Cell. 2014;156:317\u201331.","journal-title":"Cell"},{"key":"1745_CR44","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/nature09542","volume":"468","author":"WW Tsai","year":"2010","unstructured":"Tsai WW, Wang Z, Yiu TT, Akdemir KC, Xia W, Winter S, et al. TRIM24 links a non-canonical histone signature to breast cancer. Nature. 2010;468:927\u201332.","journal-title":"Nature"},{"key":"1745_CR45","doi-asserted-by":"publisher","first-page":"11612","DOI":"10.1073\/pnas.0813177106","volume":"106","author":"K Allton","year":"2009","unstructured":"Allton K, Jain AK, Herz HM, Tsai WW, Jung SY, Qin J, et al. Trim24 targets endogenous p53 for degradation. Proc Natl Acad Sci USA. 2009;106:11612\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1745_CR46","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.jhep.2014.09.026","volume":"62","author":"S Jiang","year":"2015","unstructured":"Jiang S, Minter LC, Stratton SA, Yang P, Abbas HA, Akdemir ZC, et al. TRIM24 suppresses development of spontaneous hepatic lipid accumulation and hepatocellular carcinoma in mice. J Hepatol. 2015;62:371\u20139.","journal-title":"J Hepatol"},{"key":"1745_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlr.2023.100382","volume":"64","author":"X Yao","year":"2023","unstructured":"Yao X, Dong R, Hu S, Liu Z, Cui J, Hu F, et al. Tripartite motif 38 alleviates the pathological process of NAFLD-NASH by promoting TAB2 degradation. J Lipid Res. 2023;64:100382.","journal-title":"J Lipid Res"},{"key":"1745_CR48","first-page":"808","volume":"22","author":"X Xu","year":"2024","unstructured":"Xu X, Zhu W, Miao M, Bai M, Fan J, Niu Y, et al. Activation of LONP1 by 84-B10 alleviates aristolochic acid nephropathy via re-establishing mitochondrial and peroxisomal homeostasis. Chin J Nat Med. 2024;22:808\u201321.","journal-title":"Chin J Nat Med"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01745-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01745-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01745-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T14:05:07Z","timestamp":1781877907000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01745-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":48,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1745"],"URL":"https:\/\/doi.org\/10.1038\/s41401-025-01745-x","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"assertion":[{"value":"7 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}